HealthyDirect · Growth
ITI Pharma and Healthcare Fund
ITI Mutual FundEquity Scheme - Sectoral/ Thematic4.8 years
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
- NAV
- 19.6063
- 15 Sept 2026
- 1Y
- +11.9%
- Trailing CAGR
- AUM
- ₹276.23 Cr
- 31 Aug 2026
- Volatility
- Medium
- 13.5% annualized
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+11.9%
- 3Y+19.8%
- 5Yn/a
- 10Yn/a
- SI+15.3%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+23.7%
- 3Y+15.0%
- 5Yn/a
- 10Yn/a
- Since inception
- +15.3%
- Calendar-day CAGR
- Excess 1Y
- +5.8%
- Category median, same plan and option
- 3Y win rate
- +100%
- Windows beating the median
- 3Y percentile
- 80
- Vs comparable share classes
- Worst rolling 3Y
- +17.6%
- 455 daily-ending windows
- Median rolling 3Y
- +21.5%
- Calendar-day CAGR
- Positive rolling 5Y
- n/a
- 0 daily-ending windows
- SIP 3Y XIRR
- +15.0%
- Simulated monthly SIP
Drawdown
Peak to trough from a running NAV high. Move across the path to read a date.
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 20 days
- 52 recovered episodes
- Longest recovery
- 478 days
- Trough to prior peak
- Current spell
- 11 days
- Days below latest peak
- Time below peak
- +88%
- NAV observations
13 Jan 2022 – 16 Jun 2023
Trough 17 Jun 2022 · recovered in 364 days
-17.7%
2 Jan 2025 – 24 Jun 2026
Trough 3 Mar 2025 · recovered in 478 days
-17.1%
23 Feb 2024 – 8 Apr 2024
Trough 19 Mar 2024 · recovered in 20 days
-6.1%
10 Apr 2024 – 10 Jun 2024
Trough 4 Jun 2024 · recovered in 6 days
-5.6%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
80
Vs category
86
Consistency
81
Risk-adjusted
63
Drawdown
56
Mean
73
Portfolio
31 Aug 2026 · 38 holdings · top 10 are 57.0%.
- Top 5
- 37.1%
- Top 10
- 57.0%
- Largest holding
- 12.6%
- Effective holdings
- 20.6
Sun Pharmaceutical Industries Ltd
Healthcare
12.6%
Divi's Laboratories Ltd
Healthcare
9.2%
Apollo Hospitals Enterprise Ltd
Healthcare
5.7%
Max Healthcare Institute Ltd
Healthcare
4.8%
Torrent Pharmaceuticals Ltd
Healthcare
4.8%
Decision
Quantitative read of the live evidence. An explanation can only restate what is already here.
As of 11 Sept 2026
Healthy
Engine status
Healthy
Doing its job
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 100% of rolling 3-year windows.
- Three-year return is above the category median.
- Risk-adjusted return sits above the documented risk-free proxy.
Worth investigating
Same-category peers with enough history to inspect beside this fund.
Motilal Oswal Active Momentum Fund
Motilal Oswal Mutual Fund
- 1Y
- +25.5%
- 3Y
- n/a
- Vol
- 17.1%
- Max DD
- -16.6%
- Sharpe
- 1.25
- 3Y win
- n/a
- Shallower drawdown
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility
ICICI PRUDENTIAL HOUSING OPPORTUNITIES FUND
ICICI Prudential Mutual Fund
- 1Y
- -3.4%
- 3Y
- +9.8%
- Vol
- 12.6%
- Max DD
- -16.7%
- Sharpe
- 0.67
- 3Y win
- +71%
- Lower volatility
- Shallower drawdown
Caveat: Lower trailing returns
Sundaram Multi-Factor Fund
Sundaram Mutual Fund
- 1Y
- -5.2%
- 3Y
- n/a
- Vol
- 13.5%
- Max DD
- -14.9%
- Sharpe
- -0.59
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
Caveat: Lower trailing returns
Nippon India Innovation Fund
Nippon India Mutual Fund
- 1Y
- +0.2%
- 3Y
- +13.9%
- Vol
- 14.1%
- Max DD
- -21.5%
- Sharpe
- 0.68
- 3Y win
- +100%
- Higher win rate vs category
Caveat: Higher volatility · Deeper drawdown · Lower trailing returns
Aditya Birla Sun Life Commodity Equities Fund - Global Agri Plan
Aditya Birla Sun Life Mutual Fund
- 1Y
- -2.5%
- 3Y
- +20.3%
- Vol
- 16.8%
- Max DD
- -42.2%
- Sharpe
- 0.20
- 3Y win
- n/a
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown